Research2 sources
A novel candidate biomarker for detecting premalignant and early ovarian cancer
Nature · By Kelsey R. Monson ·
The Brief · written from 2 sources
- A Nature Medicine study reports that the long noncoding RNA Tu-Stroma, measured in blood, may serve as a circulating biomarker for detecting premalignant and early ovarian cancer.
- The biomarker was tested in a cohort of 506 individuals and reportedly discriminates early-stage ovarian cancer from benign lesions with high performance.
- Two related articles on nature.com were published online on 10 November 2026 with different DOIs describing the same candidate biomarker.
Why it matters
Ovarian cancer is often detected late, and a blood-based test for premalignant and early disease could enable earlier intervention if validated in larger, independent studies.
Who’s affected
- clinicians and researchers in gynecologic oncology
- patients at elevated risk of ovarian cancer
- diagnostic test developers
- #ovarian cancer
- #biomarker
- #liquid biopsy
- #long noncoding rna
- #early detection
Nature Medicine, Published online: 10 November 2026; doi:10.1038/s41591-026-04755-2 New data suggest that the long noncoding RNA known as Tu-Stroma represents a promising new circulating biomarker for the detection of ovarian cancer at premalignant and early stages, for which…
Timeline
Study describing Tu-Stroma blood-based RNA biomarker for early ovarian cancer detection published online in Nature Medicine
nature.com
A novel candidate biomarker for detecting premalignant and early ovarian cancer
nature.com
Blood-based RNA biomarker for the early detection of ovarian cancer